Key device attributes for Somatostatin Receptor Ligand (SRL) therapy in patients with neuroendocrine tumors (NETs)

#3807

Introduction: SRL injection effectiveness, safety and adherence are similar for independent vs healthcare setting administration, but patient preferences and satisfaction with devices vary. For other injectable hormones, device ease of use has been associated with more favourable outcomes. Elucidating preferred SRL device features should help HCPs decide which device best fits individual needs.

Aim(s): To define key SRL device attributes associated with optimal injection experience by people living with NETs.

Materials and methods: In Jun-Nov 2022, patients and caregivers from 11 countries were invited to participate in a survey through INCA, WAPO, society and author efforts; newsletters to HCPs; and social media. Results (cut-off Oct 24) are shown for 143 patients and 6 caregivers using an injectable SRL for NETs.

Conference:

Presenting Author: Martin W

Authors: Martin W, Kolarova T, Marks M, Follin C, de Herder W,

Keywords: NET, neuroendocrine tumor, somatostatin receptor ligands, SRL, device, preference,